AT 101 - AbClon
Alternative Names: AT-101 - AbClon; AT101Latest Information Update: 10 Jan 2026
At a glance
- Originator AbClon
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
Most Recent Events
- 12 Jun 2025 Interim efficacy, adverse event, pharmacokinetic and pharmacodynamic data from a phase II trial in Non-Hodgkin's lymphoma presented at the 30th Congress of the European Haematology Association (EHA-2025)
- 13 Jun 2024 Efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma presented the 29th Congress of the European Haematology Association (EHA-2024)
- 31 May 2024 Adverse events and efficacy data from a phase-I/II in Non-Hodgkin's lymphoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)